Epidemiology and treatment outcomes of bone and soft tissue sarcoma in pediatric and adolescent and young adult patients in Japan: data from population-based National Cancer Registry 2016-2019.

IF 2.2 4区医学 Q3 ONCOLOGY

Cancer Investigation Pub Date : 2026-09-18 DOI:10.1080/07357907.2026.2723355

Yu Toda, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Eisuke Kobayashi, Toshiyuki Takemori, Hiroya Kondo, Shudai Muramatsu, Takahiro Higashi, Akira Kawai

{"title":"Epidemiology and treatment outcomes of bone and soft tissue sarcoma in pediatric and adolescent and young adult patients in Japan: data from population-based National Cancer Registry 2016-2019.","authors":"Yu Toda, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Eisuke Kobayashi, Toshiyuki Takemori, Hiroya Kondo, Shudai Muramatsu, Takahiro Higashi, Akira Kawai","doi":"10.1080/07357907.2026.2723355","DOIUrl":null,"url":null,"abstract":"<p><p>This Japanese population-based retrospective study using National Cancer Registry data (2016-2019) revealed age-specific disparities in treatment and outcomes of bone and soft tissue sarcomas in patients under 40 years. A total of 1,209 bone sarcoma (BS) and 3,096 soft tissue sarcoma (STS) cases were analyzed for demographics, treatment modalities, survival rates, and prognostic factors. Osteosarcoma (53%) and Ewing sarcoma (15%) were the most common BS subtypes. Pediatric patients presented more frequently with metastases and received more chemotherapy, while surgery was performed in 80% of BS cases. For STS, fibrosarcoma (19%) and rhabdomyosarcoma (13%) predominated. AYA (adolescent and young adult) patients underwent more surgeries, whereas pediatric patients received more chemotherapy/radiotherapy. Three-year overall survival rates were 67% for BS and 79% for STS. Prognosis was significantly influenced by disease extent and surgical intervention. Age was an adverse prognostic factor for STS but not for BS. This first comprehensive Japanese population-based study demonstrates treatment disparities across age groups in sarcoma care. We revealed that pediatric and AYA sarcoma care in Japan shows clear age-related disparities.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"1-13"},"PeriodicalIF":2.2000,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/07357907.2026.2723355","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This Japanese population-based retrospective study using National Cancer Registry data (2016-2019) revealed age-specific disparities in treatment and outcomes of bone and soft tissue sarcomas in patients under 40 years. A total of 1,209 bone sarcoma (BS) and 3,096 soft tissue sarcoma (STS) cases were analyzed for demographics, treatment modalities, survival rates, and prognostic factors. Osteosarcoma (53%) and Ewing sarcoma (15%) were the most common BS subtypes. Pediatric patients presented more frequently with metastases and received more chemotherapy, while surgery was performed in 80% of BS cases. For STS, fibrosarcoma (19%) and rhabdomyosarcoma (13%) predominated. AYA (adolescent and young adult) patients underwent more surgeries, whereas pediatric patients received more chemotherapy/radiotherapy. Three-year overall survival rates were 67% for BS and 79% for STS. Prognosis was significantly influenced by disease extent and surgical intervention. Age was an adverse prognostic factor for STS but not for BS. This first comprehensive Japanese population-based study demonstrates treatment disparities across age groups in sarcoma care. We revealed that pediatric and AYA sarcoma care in Japan shows clear age-related disparities.

查看原文本刊更多论文

日本儿童、青少年和年轻成人患者骨和软组织肉瘤的流行病学和治疗结果：来自2016-2019年基于人群的国家癌症登记处的数据

这项基于日本人群的回顾性研究使用了国家癌症登记处（2016-2019）的数据，揭示了40岁以下患者骨和软组织肉瘤的治疗和结果的年龄特异性差异。对1209例骨肉瘤（BS）和3096例软组织肉瘤（STS）病例进行人口统计学、治疗方式、生存率和预后因素分析。骨肉瘤（53%）和尤文氏肉瘤（15%）是最常见的BS亚型。儿科患者更常出现转移，接受更多的化疗，而80%的BS病例进行了手术。STS以纤维肉瘤（19%）和横纹肌肉瘤（13%）为主。AYA（青少年和年轻成人）患者接受更多的手术，而儿科患者接受更多的化疗/放疗。BS和STS的三年总生存率分别为67%和79%。疾病程度和手术干预对预后有显著影响。年龄是STS的不良预后因素，而不是BS。这是日本首次全面的基于人群的研究，显示了肉瘤治疗中不同年龄组的治疗差异。我们发现，日本的儿科和AYA肉瘤治疗显示出明显的年龄相关差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Investigation 医学-肿瘤学

CiteScore

3.80

自引率

4.20%

发文量

审稿时长

8.5 months

期刊介绍： Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.